loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Parsaclisib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Parsaclisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: 1426698-88-5, Incb050465, Parsaclisib [inn], Parsaclisib [usan], Incb-050465, Os7097575k
    Molecular Formula
    C20H22ClFN6O2
    Molecular Weight
    432.9  g/mol
    InChI Key
    ZQPDJCIXJHUERQ-QWRGUYRKSA-N
    FDA UNII
    OS7097575K
    Parsaclisib is an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one
    2.1.2 InChI
    InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1
    2.1.3 InChI Key
    ZQPDJCIXJHUERQ-QWRGUYRKSA-N
    2.1.4 Canonical SMILES
    CCOC1=C(C(=C(C=C1C(C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)C4CC(=O)NC4
    2.1.5 Isomeric SMILES
    CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4
    2.2 Other Identifiers
    2.2.1 UNII
    OS7097575K
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (4r)-4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

    2. 2-pyrrolidinone, 4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4r)-

    3. Incb050465

    2.3.2 Depositor-Supplied Synonyms

    1. 1426698-88-5

    2. Incb050465

    3. Parsaclisib [inn]

    4. Parsaclisib [usan]

    5. Incb-050465

    6. Os7097575k

    7. (4r)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one

    8. (4r)-4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

    9. 2-pyrrolidinone, 4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4r)-

    10. Parsaclisib (usan/inn)

    11. Parsaclisib [usan:inn]

    12. Incb050465 Free Base

    13. Parsaclisib [who-dd]

    14. Incb-050465 Free Base

    15. Parsaclisib (incb050465)

    16. Chembl4297615

    17. Schembl14736228

    18. Unii-os7097575k

    19. Bdbm272573

    20. Ex-a2638

    21. Who 10589

    22. Db14867

    23. Ac-36916

    24. Us10065963, 32c

    25. Hy-109068

    26. Cs-0033435

    27. D11437

    28. (r)-4-(3-((s)-1-(4-amino-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

    2.4 Create Date
    2015-02-02
    3 Chemical and Physical Properties
    Molecular Weight 432.9 g/mol
    Molecular Formula C20H22ClFN6O2
    XLogP32.4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count5
    Exact Mass432.1476798 g/mol
    Monoisotopic Mass432.1476798 g/mol
    Topological Polar Surface Area108 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity632
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of mature B-cell malignancies

    Post Enquiry
    POST ENQUIRY